# A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)

> **NCT03274206** · PHASE2 · UNKNOWN · sponsor: **BioLeaders Corporation** · enrollment: 126 (estimated)

## Conditions studied

- Cervical Intraepithelial Neoplasia Grade 2/3

## Interventions

- **BIOLOGICAL:** BLS-ILB-E710c
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03274206
- **Lead sponsor:** BioLeaders Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-30
- **Primary completion:** 2020-08
- **Final completion:** 2020-08
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2020-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03274206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03274206, "A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03274206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*